68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms

Sabrina Kraus; Alexander Dierks; Leo Rasche; Olivia Kertels; Malte Kircher; Andreas Schirbel; Josip Zovko; Torsten Steinbrunn; Raoul Tibes; Hans Jürgen Wester; Andreas K. Buck; Hermann Einsele; K. Martin Kortüm; Andreas Rosenwald; Constantin Lapa

doi:10.2967/jnumed.121.262206

⁶⁸Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms

Sabrina Kraus, Alexander Dierks, Leo Rasche, Olivia Kertels, Malte Kircher, Andreas Schirbel, Josip Zovko, Torsten Steinbrunn, Raoul Tibes, Hans Jürgen Wester, Andreas K. Buck, Hermann Einsele, K. Martin Kortüm, Andreas Rosenwald, Constantin Lapa

Chair of Pharmaceutical Radiochemistry

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using 68Ga-pentixafor to visualize and quantify disease involvement in myeloproliferative neoplasms (MPNs). Methods: Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia, and 2 with polycythemia vera) and 5 controls underwent 68Ga-pentixafor PET/CT. Imaging findings were compared with immunohistochemical stainings, laboratory data, and splenic volume. Results: 68Ga-pentixafor PET/ CT was visually positive in 12 of 12 patients, and CXCR4 target specificity could be confirmed by immunohistochemical staining. A significantly higher tracer uptake could be detected in the bone marrow of MPN patients (SUVmean, 6.45±2.34 vs. 4.44±1.24). Dynamic changes in CXCR4 expression determined by 68Ga-pentixafor PET/ CT corresponded with treatment response. Conclusion: 68Ga-pentixafor PET/CT represents a novel diagnostic tool to noninvasively detect and quantify the extent of disease involvement inMPNs.

Original language	English
Pages (from-to)	96-99
Number of pages	4
Journal	Journal of Nuclear Medicine
Volume	63
Issue number	1
DOIs	https://doi.org/10.2967/jnumed.121.262206
State	Published - 1 Jan 2022

Keywords

CXCR4
PET
molecular imaging
myeloproliferative neoplasms
theranostics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2967/jnumed.121.262206

Cite this

Kraus, S., Dierks, A., Rasche, L., Kertels, O., Kircher, M., Schirbel, A., Zovko, J., Steinbrunn, T., Tibes, R., Wester, H. J., Buck, A. K., Einsele, H., Kortüm, K. M., Rosenwald, A., & Lapa, C. (2022). ⁶⁸Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. Journal of Nuclear Medicine, 63(1), 96-99. https://doi.org/10.2967/jnumed.121.262206

@article{3dfc4cfd05ad41f4a63438c6a5a26256,

title = "68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms",

abstract = "C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using 68Ga-pentixafor to visualize and quantify disease involvement in myeloproliferative neoplasms (MPNs). Methods: Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia, and 2 with polycythemia vera) and 5 controls underwent 68Ga-pentixafor PET/CT. Imaging findings were compared with immunohistochemical stainings, laboratory data, and splenic volume. Results: 68Ga-pentixafor PET/ CT was visually positive in 12 of 12 patients, and CXCR4 target specificity could be confirmed by immunohistochemical staining. A significantly higher tracer uptake could be detected in the bone marrow of MPN patients (SUVmean, 6.45±2.34 vs. 4.44±1.24). Dynamic changes in CXCR4 expression determined by 68Ga-pentixafor PET/ CT corresponded with treatment response. Conclusion: 68Ga-pentixafor PET/CT represents a novel diagnostic tool to noninvasively detect and quantify the extent of disease involvement inMPNs.",

keywords = "CXCR4, PET, molecular imaging, myeloproliferative neoplasms, theranostics",

author = "Sabrina Kraus and Alexander Dierks and Leo Rasche and Olivia Kertels and Malte Kircher and Andreas Schirbel and Josip Zovko and Torsten Steinbrunn and Raoul Tibes and Wester, {Hans J{\"u}rgen} and Buck, {Andreas K.} and Hermann Einsele and Kort{\"u}m, {K. Martin} and Andreas Rosenwald and Constantin Lapa",

note = "Publisher Copyright: {\textcopyright} 2022 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2022",

month = jan,

day = "1",

doi = "10.2967/jnumed.121.262206",

language = "English",

volume = "63",

pages = "96--99",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "1",

}

Kraus, S, Dierks, A, Rasche, L, Kertels, O, Kircher, M, Schirbel, A, Zovko, J, Steinbrunn, T, Tibes, R, Wester, HJ, Buck, AK, Einsele, H, Kortüm, KM, Rosenwald, A & Lapa, C 2022, '⁶⁸Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms', Journal of Nuclear Medicine, vol. 63, no. 1, pp. 96-99. https://doi.org/10.2967/jnumed.121.262206

TY - JOUR

T1 - 68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms

AU - Kraus, Sabrina

AU - Dierks, Alexander

AU - Rasche, Leo

AU - Kertels, Olivia

AU - Kircher, Malte

AU - Schirbel, Andreas

AU - Zovko, Josip

AU - Steinbrunn, Torsten

AU - Tibes, Raoul

AU - Wester, Hans Jürgen

AU - Buck, Andreas K.

AU - Einsele, Hermann

AU - Kortüm, K. Martin

AU - Rosenwald, Andreas

AU - Lapa, Constantin

PY - 2022/1/1

Y1 - 2022/1/1

N2 - C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using 68Ga-pentixafor to visualize and quantify disease involvement in myeloproliferative neoplasms (MPNs). Methods: Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia, and 2 with polycythemia vera) and 5 controls underwent 68Ga-pentixafor PET/CT. Imaging findings were compared with immunohistochemical stainings, laboratory data, and splenic volume. Results: 68Ga-pentixafor PET/ CT was visually positive in 12 of 12 patients, and CXCR4 target specificity could be confirmed by immunohistochemical staining. A significantly higher tracer uptake could be detected in the bone marrow of MPN patients (SUVmean, 6.45±2.34 vs. 4.44±1.24). Dynamic changes in CXCR4 expression determined by 68Ga-pentixafor PET/ CT corresponded with treatment response. Conclusion: 68Ga-pentixafor PET/CT represents a novel diagnostic tool to noninvasively detect and quantify the extent of disease involvement inMPNs.

AB - C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using 68Ga-pentixafor to visualize and quantify disease involvement in myeloproliferative neoplasms (MPNs). Methods: Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia, and 2 with polycythemia vera) and 5 controls underwent 68Ga-pentixafor PET/CT. Imaging findings were compared with immunohistochemical stainings, laboratory data, and splenic volume. Results: 68Ga-pentixafor PET/ CT was visually positive in 12 of 12 patients, and CXCR4 target specificity could be confirmed by immunohistochemical staining. A significantly higher tracer uptake could be detected in the bone marrow of MPN patients (SUVmean, 6.45±2.34 vs. 4.44±1.24). Dynamic changes in CXCR4 expression determined by 68Ga-pentixafor PET/ CT corresponded with treatment response. Conclusion: 68Ga-pentixafor PET/CT represents a novel diagnostic tool to noninvasively detect and quantify the extent of disease involvement inMPNs.

KW - CXCR4

KW - PET

KW - molecular imaging

KW - myeloproliferative neoplasms

KW - theranostics

UR - http://www.scopus.com/inward/record.url?scp=85123324429&partnerID=8YFLogxK

U2 - 10.2967/jnumed.121.262206

DO - 10.2967/jnumed.121.262206

M3 - Article

C2 - 34049979

AN - SCOPUS:85123324429

SN - 0161-5505

VL - 63

SP - 96

EP - 99

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 1

ER -